Lv4
600 积分 2022-12-07 加入
Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade
16天前
已完结
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study
1个月前
已完结
Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions
1个月前
已完结
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
1个月前
已完结
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo
2个月前
已完结
Durvalumab and T-DXd Synergistically Promote Apoptosis of Cholangiocarcinoma Cells by Downregulating EGR1 Expression Through Inhibiting P38 MAPK Pathway
4个月前
已完结
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
4个月前
已完结
Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study
5个月前
已关闭
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
6个月前
已完结
皖公网安备34019202002308
